Cite
HARVARD Citation
Popat, S. et al. (n.d.). 3085 Second-line afatinib vs erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung: patient-reported outcome (PRO) data from the global LUX-Lung 8 (LL8) Phase III trial. European journal of cancer. pp. S626-S627. [Online].